Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female aged 18-40 years old or 65 years or older at the time of the vaccination.~* Written informed consent obtained from the subject.~* Free of an acute aggravation of the health status as established by clinical evaluation (medical history and medical history directed examination) before entering into the study.~* If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period.~* Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study.~* Planned administration of a vaccine not foreseen by the study protocol during the entire study period.~* Planned administration of an influenza vaccine other than the study vaccines during the entire study period.~* Vaccination against influenza since January 2007 (with 2007/2008 or 2006/2007 influenza vaccine).~* Administration of more than 14 days of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination~* Hypersensitivity to a previous dose of influenza vaccine.~* Allergy to any component of the vaccine.~* Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality.~* Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature\<37.5ºC (99.5ºF).~* Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study.~* Any medical conditions in which IM injections are contraindicated.~* Lactating female or female planning to become pregnant or to discontinue contraceptive precautions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Influenza vaccine GSK576389A formulation 1 Group (Type: EXPERIMENTAL): Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
- Influenza vaccine GSK576389A formulation 2 Group (Type: EXPERIMENTAL): Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
- Influenza vaccine GSK576389A formulation 3 Group (Type: EXPERIMENTAL): Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
- Influenza vaccine GSK576389A formulation 4 Group (Type: EXPERIMENTAL): Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
- Influenza vaccine GSK576389A formulation 5 Group (Type: EXPERIMENTAL): Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
- Influenza vaccine GSK576389A formulation 6 Group (Type: EXPERIMENTAL): Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
- Influenza vaccine GSK576389A formulation 7 Group (Type: EXPERIMENTAL): Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
- Influenza vaccine GSK576389A formulation 8 Group (Type: EXPERIMENTAL): Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
- Fluarix elderly Group (Type: ACTIVE_COMPARATOR): Subjects aged ≥65 years received one dose of Fluarix vaccine.
- Fluarix young Group (Type: ACTIVE_COMPARATOR): Subjects aged 18-40 years received one dose of Fluarix vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete